Liver X Receptor

亜型選択性的な製品

Liver X Receptor製品

  • All (15)
  • Liver X Receptor拮抗剤(1)
  • Liver X Receptor作動薬(7)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S2630 GW3965 HCl GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.
Regen Ther, 2024, 25:229-237
Cell Death Dis, 2023, 14(2):85
Mol Oral Microbiol, 2023, 10.1111/omi.12447
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
Front Immunol, 2022, 13:848367
J Anim Sci Biotechnol, 2022, 13(1):120
Commun Biol, 2022, 5(1):132
S8390 LXR-623 LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.
Acta Neuropathol Commun, 2022, 10(1):40
Cancers (Basel), 2022, 14(16)3873
EMBO Mol Med, 2019, 11(10):e10769
S7934 SR9243 SR9243 is a potent and selective LXR inverse agonist.
Front Immunol, 2021, 12:732102
FEBS Lett, 2016, 590(11):1614-29
S6427 AZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.
J Clin Invest, 2019, 129(3):1129-1151
S8689 Abequolixron (RGX-104) Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099 GSK3987 GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.
E1142 GSK2033 GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.
S2630 GW3965 HCl GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.
Regen Ther, 2024, 25:229-237
Cell Death Dis, 2023, 14(2):85
Mol Oral Microbiol, 2023, 10.1111/omi.12447
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
Front Immunol, 2022, 13:848367
J Anim Sci Biotechnol, 2022, 13(1):120
Commun Biol, 2022, 5(1):132
S8390 LXR-623 LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.
Acta Neuropathol Commun, 2022, 10(1):40
Cancers (Basel), 2022, 14(16)3873
EMBO Mol Med, 2019, 11(10):e10769
S7934 SR9243 SR9243 is a potent and selective LXR inverse agonist.
Front Immunol, 2021, 12:732102
FEBS Lett, 2016, 590(11):1614-29
S6427 AZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.
J Clin Invest, 2019, 129(3):1129-1151
S8689 Abequolixron (RGX-104) Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099 GSK3987 GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.
E1142 GSK2033 GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.
S2630 GW3965 HCl GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.
Regen Ther, 2024, 25:229-237
Cell Death Dis, 2023, 14(2):85
Mol Oral Microbiol, 2023, 10.1111/omi.12447
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
Front Immunol, 2022, 13:848367
J Anim Sci Biotechnol, 2022, 13(1):120
Commun Biol, 2022, 5(1):132
S8390 LXR-623 LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.
Acta Neuropathol Commun, 2022, 10(1):40
Cancers (Basel), 2022, 14(16)3873
EMBO Mol Med, 2019, 11(10):e10769
S7934 SR9243 SR9243 is a potent and selective LXR inverse agonist.
Front Immunol, 2021, 12:732102
FEBS Lett, 2016, 590(11):1614-29
S6427 AZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.
J Clin Invest, 2019, 129(3):1129-1151
S8689 Abequolixron (RGX-104) Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099 GSK3987 GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.

Liver X Receptor阻害剤の選択性比較

Tags: Liver X Receptor inhibitor|Liver X Receptor agonist|Liver X Receptor activator|Liver X Receptor inducer|Liver X Receptor antagonist|Liver X Receptor signaling pathway|Liver X Receptor assay kit